A systematic review of the literature was performed to gather all official recommendations on the prevention in infants of allergic manifestations (AM), and, more specifically, atopic dermatitis (AD), by using hydrolyzed infant formulas (HF) such as partially or extensively hydrolyzed formula (PHF; EHF). METHODS: OVID MEDLINE ® and the grey literature were searched by two reviewers using the keywords AM, AD, prevention and guidelines. A third person acted as adjudicator in case of disagreement. Of interest were recommendations pertaining to the prevention of AM issued by national or regional associations of medical professionals. RESULTS: This review yielded 11 sets of guidelines published for Australia, France, Germany, Spain, Switzerland (all nϭ1), Europe and the US (both nϭ3) between 1999 and 2010. Most guidelines included AD either specifically (nϭ3) or in the broad context of AMs. Six guidelines (of which 2 recommended PHF over EHF) endorsed the use of HFs for the prevention of AM in "at risk" infants when exclusive breastfeeding was not or no longer possible. Two other publications did not explicitly recommend HFs, but rather formulas with a documented reduced allergenicity. The need for an appropriate level of nutritional support was stressed in one publication. Five guidelines acknowledged that not all HFs have the same protective benefit. . Four publications underlined the importance of sound clinical evidence when determining the preventive efficacy of HFs. None of the guidelines based their recommendations on recent evidence from meta-analyses focusing on a specific brand of PHF NAN-HA ® . CONCLUSIONS: HFs and specifically PHFs are endorsed for the prevention of AMs. The need for a strong validity and universality of the clinical evidence and methodology is acknowledged by national or regional medical associations. Hence, recent evidence regarding the preventive efficacy of a specific brand of PHF, NAN-HA ® , should provide the basis for new recommendations.
OBJECTIVES: Patch testing is a well-established method to determine whether contact sensitization to certain agents has occurred and it can directly influence the clinical outcome of patients with allergic contact dermatitis (ACD) where detection of causative allergens is crucial for appropriate prevention and treatment. Its positive predictive value, however, is influenced by many variables. In particular, not all patients referred for patch testing actually have ACD and not all positive reactions are clinically relevant. The objective of our study was to develop an outcome indicator of patch testing. METHODS: We identified and measured as a possible indicator the ratio of patients with allergic and/or photo-allergic contact dermatitis clinically cured/improved as a result of identification of relevant allergens. Patients with positive reactions considered relevant to their current dermatitis were interviewed by telephone 2 months after patch/photo-patch testing in order to assess their clinical outcome in relation to the recommended elimination of supposedly relevant allergens. We parallely evaluated the prevalence of referral diagnosis different from ACD in patients whose test results were negative/non-relevant. RESULTS: Over a 4-year period positive reactions were seen in 1397 out of 2857 tested patients. Relevance was considered current in 578 subjects, and 506 of them were interviewed. Remission/significant improvement following allergen(s) contact avoidance was reported by 431 patients, the outcome indicator (431/506) thus scoring 85.2%. Among the 75 patients who reported no improvement, 41 had not avoided contact with the offending substance(s), 17 had other persistent concomitant skin conditions, and 17 were unchanged despite elimination of the alleged relevant allergens. The likely diagnoses of patients whose test results were negative/non-relevant were: non-eczematous diseases (39% of total patients), endogenous eczema (22%), irritant contact dermatitis (10%), unknown (5%), possible ACD from unidentified haptens (4%). CONCLUSIONS: The ratio of relevantly patch-test-positive patients resolved/improved after allergen avoidance is a useful patch-testing outcome indicator.
PRS75 HEALTH TECHNOLOGY APPRAISAL OF NEW DRUGS: ARE WE GETTING IT RIGHT?
Gordon J 1 , Karnon J 2 1 University of Adelaide, Adelaide, SA, Australia, 2 University of Adelaide, Adelaide, South Australia, Australia OBJECTIVES: A particular challenge for economic evaluation of new pharmaceuticals is to address the potential for conflict between 1) the available evidence that informs decisions about reimbursement coverage, and 2) the reality of how products are used in clinical practice. The aim of this study is to explore the issue of divergence between actual and evaluated drug pathways and resultant consequences for the appropriateness of technology appraisals and reimbursement coverage decisions. METHODS: We develop a generic decision analytic model to illustrate the issue of divergence between actual and evaluated drug pathways arising from a new product changing the number of lines of therapy available to patients, rather than displacing existing therapies. Under this generic model, incremental costs and effects are potentially affected by response to therapy and the clinical decision to maintain or switch treatment. The potential effects on the estimated cost-effectiveness of new drugs from the misspecification of the drug pathway are illustrated using COPD as a case study disease area and prescription utilisation data from Australia. RESULTS: In the case of treatments for COPD, cost-effectiveness of new therapies is overestimated when displacement is assumed, but the real-world utilisation of new products involves additions to reimbursement schedules without displacement and when effect size decreases with therapy line. We define this as pathway misspecification bias and consider that it may arise in all disease areas and drug classes. We demonstrate that the size of the bias is positively related to the proportion of non-responders. CONCLUSIONS: We demonstrate that without provision to withdraw funding from existing lines of therapy, cost-effectiveness analysis to inform reimbursement decision-making should be expanded to include further routine modelling of the likely use of products in clinical practice. We demonstrate that providing for the withdrawal of funding for existing technologies may provide for more efficient funding decisions. 
PRS76 SYSTEMATIC LITERATURE REVIEW OF CONCEPTUAL MODELS TO INFORM ECONOMIC MODELLING IN COPD

OBJECTIVES:
To identify evidence gaps for future economic modelling of Chronic Obstructive Pulmonary Disease (COPD) by reviewing published Conceptual Models and studies reporting associations between end-points and disease outcomes. METHODS: A systematic literature search was undertaken to identify English language publications since 2000 in Medline and Embase describing Conceptual Models of COPD and studies reporting associations between end-points and disease outcomes. Studies were reviewed against inclusion/exclusion criteria and those including therapeutic interventions were excluded at screening. RESULTS: Fortyone published papers were identified: 7 conceptual models of COPD and 34 articles on associations between endpoints and disease outcomes. Of the 7 conceptual models, 6 described single aspects of COPD (cognitive function, dyspnoea, brain function, design of patient related interventions, activity and functional performance). Only 1 described a broader set of determinants of health status in COPD patients (physiological functioning, patient complaints, functional impairment and quality of life.) 2 review papers on cognitive function and functional performance and 1 reporting determinants of functional performance and dyspnoea based on patient/expert interviews were identified. 31 studies using regression analyses to estimate associations between relevant parameters in COPD, including symptoms (mainly dyspnoea), health status, exercise, lung function, exacerbations, quality of life, biomarkers, co-morbidities, mortality and healthcare utilization were found. No studies on the use of conceptual models for economic modelling in COPD were identified. None of the studies presented a comprehensive set of determinants of disease progression and outcomes. CONCLUSIONS: It is recommended that models used to support economic evaluations of health care interventions are based on conceptual models capturing all relevant aspects of the disease and outcomes of value. The available evidence does not provide a full spectrum of relationships between diagnosis, disease progression and outcomes needed for a comprehensive disease based economic model in COPD. 
PRS77
APPLICATION OF INNOVATIVE METHODS TO IDENTIFY AND CHARACTERIZE DIFFERENTIAL RESPONDERS IN CLINICAL TRIALS OF COPD: THE USE OF MIXTURE MODELS
OBJECTIVES:
Applying innovative methods to clinical trial data to identify and characterize unobserved subgroups of differential responders. METHODS: Data from three COPD clinical trials was retrospectively analysed using Growth Mixture Models (GMMs): INHANCE (indacaterol 150g and 300g vs tiotropium 18g and placebo); INLIGHT-2 (indacaterol 150g vs salmeterol 50g and placebo); and IN-VOLVE (indacaterol 300g and 600g vs formoterol 12g and placebo). GMMs were conducted on SGRQ Symptoms Domain data at baseline, 12 weeks, and six months to identify unobserved subgroups. Baseline characteristics were compared between emergent subgroups of differential responders in post hoc analyses. RESULTS: Within INHANCE and INLIGHT-2, two subgroups of patients emerged per treatment arm: responders (improvement) and non-responders (little change/deterioration). Within INOLVE, three subgroups of patients emerged per treatment arm: responders, non-responders, and partial-responders. When responders were analysed separately, mean treatment effects in terms of SGRQ Symptom scores were generally larger than when all patients were included: INHANCE responder improvements ranged from 8 -12 units compared with 7-14 for all patients; INLIGHT-2 responder improvements were 3 -13 units versus 3 -8 for all patients; INVOLVE responder improvements were 5 -17 units vs 3 -11 for all patients. Within each trial, responders made up the largest proportion of the sample (55% -82%) but non-/partial-responder groups were large enough and different enough to dampen treatment effects when group means were analyzed as a whole. Responders had significantly better baseline SGRQ Symptom scores than non-responders. Further significant differences were found between non-responders, partial-responders and responders in terms of smoking history, age, and breathlessness.
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V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 -A 5 1 0 CONCLUSIONS: GMMs have the potential to increase understanding of treatment effects and identify patients more likely to benefit from treatment. The ability of baseline characteristics to predict responders/non-responders needs to be tested prospectively. OBJECTIVES: To investigate the associations between ocular discomfort, compliance and efficacy of IOP lowering drugs. METHODS: This was a prospective observational survey. Centres were selected at random from the CEGEDIM list. Consecutive patients treated with an IOP lowering fixed combination drug (prostaglandin analogues excluded) were included. IOP was collected at two visits (delay fixed by the investigator). Self-reported compliance measured by validated questionnaires (EDSQ, TSQM and TEO) and self-reported ocular discomfort (13 items with a focus at instillation and during the day) based on a questionnaire developed according to international patient reported outcome recommendations were collected at the last visit. Patients were classified into 3 groups of compliance (good, minor and major issues) using the TEO published algorithm. Comparisons between compliance groups were made by ANOVA and chi-square tests. Adjustments were made for confounding variable unbalances. RESULTS: 410 patients (66 years old, 237 females, 101 ocular hypertensions) were included. 32.9% reported good compliance, 55.9% minor and 11.2% major compliance issues. Patients reporting either red eyes (Pϭ0.02), stinging (Pϭ0.007), feeling of sand in the eyes (Pϭ0.0009), dry eye (Pϭ0.02), or blurry vision (Pϭ0.002) were more likely to report compliance issues. Patients in the good compliance group reported 3.2 ocular discomfort concerns, 4.5 in the minor and 5.2 in the major compliance issue group (Pϭ0.0002). The probabilities to report no concern were 24.2%, 12.7% and 11.9% (Pϭ0.02), respectively. An association between IOP control and compliance was reported in the group of patients that did not have a change in treatment at the first visit: patients in the good compliance group had an IOP decrease of 0.9 mmHg, 0.3 mmHg in the minor and a 0.2 mmHg increase in the major compliance issue group. CONCLUSIONS: Ocular discomfort issues reported by patients might impact compliance leading to poor IOP control. 
Sensory Systems Disorders -Clinical Outcomes
PSS2 PREVALENCE, DEMOGRAPHICS AND TREATMENT CHARACTERISTICS OF VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR EDEMA IN A REPRESENTATIVE CANADIAN COHORT
OBJECTIVES:
To determine the prevalence, demographics and treatment characteristics of patients with visual impairment (VI) due to diabetic macular edema (DME) in a real-world Canadian setting. METHODS: Records from a longitudinal population-based database of more than 170,000 patients in 53 family practice clinics in southwestern Ontario, Canada were analyzed between January 1, 2008 to December 31, 2009. Patient records were limited to those aged 18 years of age and older. These records contained chart-abstracted information such as visit diagnosis, medications and consultation notes. Initial extractions of control, diabetic and DME patients with VI, defined as best corrected visual acuity Յ20/40 in the DME eye, were accomplished utilizing International Classification of Disease codes (ICD9/ ICD10); reviewing patient charts for text entries of symptoms that supported a diagnosis of diabetes and DME and concomitant comorbidity; and reviewing patient treatment records unique to DME with VI including consultation notes and hospital discharge summaries. Demographic characteristics, comorbidities, and treatment were reported. RESULTS: 8368 patients with type 1 or 2 diabetes and a control cohort of 76,077 patients were extracted for this analysis. Among diabetic patients, prevalence of DME was 15.7%. Average duration of diabetes among patients with DME was 19 years. More patients with DME had hypertension (66%), or vascular disease (28%) than the control cohort (pϽ0.05). The prevalence of VI due to DME was 2.56%. Mean age was 64Ϯ17. In patients with VI due to DME, 53% had focal and 47% had diffuse edema. For both focal and diffuse edema, the most common treatment was laser monotherapy, used in 62% and 53% of cases, respectively. CONCLUSIONS: : In a real-world setting, among patients with diabetes, we observed the prevalence of VI due to DME at 2.56% . Laser monotherapy was the most common treatment. 
PSS3 INCIDENCE AND CHARACTERISTICS OF PATIENTS WITH MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION IN A REPRESENTATIVE CANADIAN COHORT
OBJECTIVES:
Retinal vein occlusion (RVO) has an abrupt onset and is an important cause of visual morbidity. Macular edema (ME) is the most common cause of visual impairment (VI) in patients with RVO. The Canadian incidence of VI due to ME secondary to RVO is unknown. This study aimed to determine the annual incidence and characteristics of patients with ME secondary to branch RVO (BRVO) and central RVO (CRVO) in a real-world Canadian setting. METHODS: Records from a lon-gitudinal population-based database of more than 170,000 patients in 53 family practice clinics in southwestern Ontario, Canada were analyzed between January 1, 2008 and December 31, 2009. These records contained chart-abstracted information such as visit diagnosis, medications and consultation notes. Initial extractions of control cohort and RVO patients with ME and VI (defined as best corrected visual acuity Յ20/40 in the RVO eye), were accomplished utilizing International Classification of Disease codes (ICD9/ICD10); reviewing patient charts for text entries of symptoms that supported a diagnosis of RVO and concomitant comorbidity; and reviewing patient treatment records unique to RVO including consultation notes and hospital discharge summaries. Demographic characteristics and comorbidities were reported. RESULTS: Seventy-three (53 with BRVO and 20 with CRVO) of 47,166 patients over 40 years (mean age 61Ϯ17 years) with new diagnosis of RVO and a control cohort of 76,077 patients were extracted for this analysis. The annual incidence of VI due to ME secondary to BRVO and CRVO was 0.056% and 0.021%, respectively. More RVO patients had hypertension (68 vs. 18%) or dyslipidemia (16 vs. 10%) than control cohort (pϽ0.05). One-quarter of RVO patients had a history of vascular disease, primarily MI and stroke. CONCLUSIONS: In a real-world setting, the annual incidence of VI due to ME secondary to BRVO and CRVO was 0.056% and 0.021%, respectively. RVO is associated with several vascular comorbidities.
PSS4 LONGER TERM PATIENT BENEFITS OF POLYQUAD® PRESERVATIVE INSTEAD OF BENZALKONIUM CHLORIDE IN PROSTAGLANDIN EYE DROPS: A MICROSIMULATION MODEL IN OCULAR HYPERTENSION AND OPEN-ANGLE GLAUCOMA
Gerlier L 1 , Lamotte M 1 , Berdeaux G 2 , Verboven Y 3 , Pfeiffer N 4 1 IMS Consulting Group, Vilvoorde, Belgium, 2 ALCON RESEARCH LTD, France, 3 Alcon Research Ltd, Puurs, Belgium, 4 University Medical Centre, Mainz, Germany OBJECTIVES: The presence of the preservative benzalkonium chloride (BAK) at 0.01% concentration in commercialized prostaglandin eye drops for glaucoma is known to increase the risk of ocular surface disease (OSD), which worsens with the extent of exposure to BAK. We aimed to estimate longer term clinical outcomes with travoprost preserved with Polyquad® 0.001% instead of BAK. METHODS: A Markov microsimulation model was developed (TreeAge) to assess the development of OSD and disease progression (Mean Defect [MD], in db) over 10 years, in patients initiating travoprost with Polyquad® followed by travoprost/beta-blocker fixed combination vs. the same sequence using BAK-preserved drops. Initial patient's characteristics came from distributions on age (normal), sex, OSD presence, disease stage (uniform) and anticipated progression rates (triangular). The risk of developing OSD in aging population was derived from a US incidence study, multiplied by independent risk factors (age, sex, duration and amount of BAK-containing drops received). Rates of disease progression (db/year) came from landmark studies in OHT/glaucoma, multiplied by independent accelerating factors (disease stage, treatment line, OSD severity, non-compliance). Compliance was expected by experts to be 20% (absolute) better with Polyquad® vs. BAK-preserved drops. RESULTS: Using 3000 trials (mean age 57 years, 57% female, 14% with initial OSD, mean MD -4db), 47.6% [41.5-53.6%] of patients receiving in first and second line BAK-preserved travoprost treatments are expected to have OSD at 10 years versus 31.7% [28.5-35.1%] with Polyquad®. In OHT/early glaucoma patients, the model predicted the progression to advanced glaucoma (MDϽ-12db) of 13.2% [12.0-14.4%] with Polyquad® versus 18. 1% [16.7-19 .5%] with BAK. In patients diagnosed with moderate glaucoma, 1.9% [1.4-2.4%] versus 5.6% [4.8-6.4%] progressed to blindness (MDϽ-24db) respectively. CONCLUSIONS: The model estimated that OSD incidence was reduced by 33% and glaucoma disease progression was significantly less frequent after 10 years of use of Polyquad® versus BAK-containing travoprost eye drops. 
PSS5 VISUAL FIELD EVOLUTION IN GLAUCOMA PATIENTS PRESENTING WITH DIFFERENT DISEASE STAGES: RESULTS FROM AN OBSERVATIONAL STUDY
OBJECTIVES:
The progression of glaucoma is measured by a Mean Defect (MD) of the perimetry in decibels (db), from an early disease stage (Ͻ6db loss), until moderate (6-12db loss), advanced stages (12-24db loss) and eventually blindness (Ͼ24db loss). The rate of disease progression is highly variable between individuals and hard to predict. The objective of this study was to analyze the change in MD of glaucoma patients in a real-life setting in Germany. METHODS: We analyzed patient-level data from a German observational study in ocular hypertension (OHT) and glaucoma, with retrospective collection of MD measures (db). Descriptive statistics were derived on the rate of disease progression (db loss/year, obtained by dividing the change in MD by the duration of observation). The change in MD in best eye between the time of first treatment until last MD measure was included in a generalized linear regression, adjusting for age, sex, presence of cataract, time since first treatment, initial MD and initial glaucoma stage (OHT, early/moderate or advanced). RESULTS: MD data was available for 57 patients (53% female, mean age 67 ϩ/Ϫ12 years). The mean (SD) time from first treatment until last MD measure was 7.0 (3.7) years. The mean (SD) MD was -4.5db (4.7) at first treatment and -6.0db (6.8) at last assessment (i.e. average rate of progression of -0.21db/year, all stages). In 12 OHT patients, 50% had no MD worsening, while 50% lost on average -0.26db/ year. Based on the adjusted analysis, the initial diagnosis was significantly associated with the amount of db loss over time (early/moderate glaucoma -0.19db/year ϩ/Ϫ0.13, advanced -0.66db/year ϩ/Ϫ0.22, pϭ0.038). CONCLUSIONS: The rates of disease progression measured over more than 7 years in glaucoma patients was A502
